Relay Therapeutics, Inc.
RLAY
$12.78
-$0.44-3.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -57.14% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -57.14% | -- | |||
| Cost of Revenue | 25.25% | -17.02% | |||
| Gross Profit | -36.94% | 27.33% | |||
| SG&A Expenses | -18.88% | 8.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.67% | -13.01% | |||
| Operating Income | -24.88% | 21.72% | |||
| Income Before Tax | -33.52% | 25.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -33.52% | 25.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.52% | 25.97% | |||
| EBIT | -24.88% | 21.72% | |||
| EBITDA | -25.28% | 21.74% | |||
| EPS Basic | -28.75% | 26.41% | |||
| Normalized Basic EPS | -23.58% | 23.33% | |||
| EPS Diluted | -28.75% | 26.41% | |||
| Normalized Diluted EPS | -23.58% | 23.33% | |||
| Average Basic Shares Outstanding | 3.72% | 0.59% | |||
| Average Diluted Shares Outstanding | 3.72% | 0.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||